

Guidance on the renewal of the authorisation of feed additives

EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP),
Vasileios Bampidis, Giovanna Azimonti, Maria de Lourdes Bastos, Henrik Christensen, Birgit
Dusemund, Maryline Kouba, Mojca Kos Durjava, Marta López-Alonso, Secundino López Puente,
Francesca Marcon, Baltasar Mayo, Alena Pechová, Mariana Petkova, Fernando Ramos, Yolanda
Sanz, Roberto Edoardo Villa, Ruud Woutersen, Montserrat Anguita, Jaume Galobart, Irene Muñoz
Gujardo and Matteo Lorenzo Innocenti

Abstract

This guidance document is intended to assist the applicant in the preparation and the presentation of an application, as foreseen in Article 7.6 of Regulation (EC) No 1831/2003, for the renewal of the authorisation of additives for use in animal nutrition.

© 2020 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf of European Food Safety Authority.

Keywords

Guidance, renewal, feed additives, safety, efficacy

22 **Table of Contents**

23 Abstract1

24 Keywords1

25 1 Introduction3

26 1.1 Background and Terms of Reference as provided by the requestor3

27 1.2 Scope of the guidance3

28 2 General principles on the assessment of applications for renewal of the authorisation.....4

29 3 Contents of the technical dossier5

30 3.1 Section I – Summary of the dossier5

31 3.2 Section II - Identity, characterisation and conditions of use of the additive, methods of

32 analysis.....5

33 3.3 Section III - Safety7

34 3.3.1 General requirements.....7

35 3.3.2 Safety for the target species7

36 3.3.3 Safety for the consumer.....8

37 3.3.4 Safety for user10

38 3.3.5 Safety for the environment.....11

39 3.4 Efficacy11

40 3.5 Post-market monitoring11

41 4 Means to provide evidence of safety (and efficacy, when relevant)12

42 4.1 Extensive literature searches12

43 4.2 New studies14

44 5 Other requests linked to the application for the renewal of the authorisation14

45 6 References14

46 Glossary and/or abbreviations and/or acronyms16

47

48 Introduction

49 Background and Terms of Reference as provided by the requestor

50 Regulation (EC) No 1831/2003¹ establishes the rules governing the Community authorisation of
51 additives for use in animal nutrition. Moreover, Regulation (EC) No 429/2008² provides detailed rules
52 for the implementation of Regulation (EC) No 1831/2003 as regards the preparation and the
53 presentation of applications as well as the assessment and the authorisation of feed additives.

54 During the course of the years, the Panel on Additives and Products or Substances used in Animal
55 Feed (FEEDAP Panel) has adopted a series of guidance documents which aim at complementing
56 Regulation (EC) No 429/2008 to help the applicants in the preparation and submission of technical
57 dossiers for the authorisation of additives for use in animal nutrition according to Regulation (EC)
58 No 1831/2003. The FEEDAP Panel has recently updated most of these guidance documents. The
59 most up to date guidance documents cover all aspects from the characterisation of the additives,
60 safety for the target species, consumers and the environment, and the efficacy.

61 However, the guidance document for the renewal of the authorisations of feed additives (EFSA
62 FEEDAP Panel, 2013) was not included in the last update exercise.

63 In view of the above, the European Food Safety Authority (EFSA) asks its FEEDAP Panel to revise
64 and update the guidance document for the renewal of the authorisations of feed additives,
65 considering the changes introduced in the other guidance documents, the recent scientific
66 developments and the Panel's experience gained during the last years in the assessment of
67 applications for the renewal of the authorisations. The FEEDAP Panel is also invited to consider
68 initiatives like preparatory info-sessions or public consultations of the draft guidance document. The
69 relevant comments received in either step will have to be considered and addressed in the final
70 version of the guidance document.

71 Scope of the guidance

72 This guidance document is part of a series of documents intended to assist the applicant in the
73 preparation and presentation of its application for authorisation of a feed additive, as foreseen in
74 Article 7.6 of Regulation (EC) No 1831/2003. This document does not substitute for the obligation
75 of an applicant to comply with the requirements of Regulation (EC) No 1831/2003 and its
76 implementing rules (Commission Regulation No 429/2008). This document is intended to provide
77 guidance to applicants for the preparation and presentation of an application of the renewal of an
78 authorisation for additives used in animal nutrition. This guidance has four main sections after an
79 introduction. The first one deals with the general principles of the assessment of applications for the
80 renewal of the authorisation of feed additives. Section 2 details the type of information which is
81 required in the different sections of the dossier, while Section 3 provides an overview of common
82 methodologies to fulfil the requirements of Section 2. Finally, Section 4 provides information on the
83 requirements for those applications which include other requests in addition to the renewal.

¹ Regulation (EC) No 1831/2003 of the European Parliament and of the Council of 22 September 2003 on additives for use in animal nutrition. OJ L 268, 18.10.2003, p. 29.

² Commission Regulation (EC) No 429/2008 of 25 April 2008 on detailed rules for the implementation of Regulation (EC) No 1831/2003 of the European Parliament and of the Council as regards the preparation and the presentation of applications and the assessment and the authorisation of feed additives. OJ L 133, 22.5.2008, p. 1.

84 1 General principles of the assessment of applications for renewal 85 of the authorisation

86 The main objectives of the renewal of the authorisation of a feed additive are i) the demonstration
87 of compliance of the additive placed in the market with the conditions of the existing authorisation,
88 and ii) the demonstration that in the light of the current knowledge, the additive remains safe under
89 the approved conditions for the target species, the consumers, the users and the environment.

90 The dossier must enable an assessment to be made of an additive based on the current state of
91 knowledge and permit verification of the compliance of these additives with the fundamental
92 principles for the renewal of the authorisation, which are laid down in Article 14 of [Regulation \(EC\)](#)
93 [No 1831/2003](#).

94 The information to be submitted and the extent of it will depend on the additive itself and its nature,
95 the category/functional group, the target animals and the conditions of use. The applicant should
96 refer to [Regulation \(EC\) No 429/2008](#) in order to evaluate which information should be submitted
97 with the application. Reasons must be given for the omission from the dossier of any data prescribed
98 there.

99 Reference can be made to published studies to fulfil the requirements listed in the guidance provided
100 that the active substance/agent in literature studies is identical to that under application or, if not,
101 would still allow conclusions on the additive under application to be drawn. In such a case a
102 justification for read-across should be given.

103 Studies involving animals should respect the rules on animal welfare laid down by the European
104 Union (EU) legislation, particularly those listed in Directive 63/2010/EU³. The use of methods refining
105 or replacing the tests using experimental animals or reducing the number of animals used in these
106 tests shall be encouraged. Such methods must provide the same level of assurance as the methods
107 they aim to replace.

108 When preparing the application for the renewal of feed additives, the applicant should consider the
109 most up-to-date scientific knowledge, the current scientific/methodological approaches and should
110 follow the most updated guidance documents of EFSA and any other relevant guidance documents.
111 When studies are needed to support the safety or the efficacy of an additive, these should follow
112 the relevant guidance documents of the FEEDAP Panel.

113 It is recognised that applicants may include in an application for renewal of an authorisation also
114 requests for new uses of the additive (e.g., new target species) and/or modifications of the
115 conditions of authorisation. Although these requests would not be considered strictly as a renewal
116 of an authorisation, they can be addressed in the application for renewal provided that the
117 application to the European Commission reflects the request(s) and the dossier contains all the
118 information necessary for the assessment in line with the requirements detailed in Regulation (EC)
119 No 429/2008 and the applicable guidance documents (see Section 4 of this guidance document).

³ Directive 2010/63/EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes OJ L 276, 20.10.2010, p. 33–79

120 2 Contents of the technical dossier

121 Each technical dossier should be stand-alone and contain all the information necessary to allow EFSA
122 to perform an assessment of the application in line with the requirements listed above. The dossier
123 shall be structured in accordance with the numbering system proposed in the [Regulation \(EC\) No](#)
124 [429/2008](#).

125 The dossier shall include references and copies of all published scientific data mentioned and the
126 copies of any other relevant opinions which have already been produced by any recognised scientific
127 body. All studies submitted should clearly refer to the same additive (active substance/agent) as the
128 one subject to the application for renewal of the authorisation.

129 Where the information included in the renewal dossier is substantially the same as that submitted
130 in a previous application already assessed by EFSA, the applicant should clearly indicate (e.g. by
131 using different colours) which parts of the dossier were already submitted, which are updated or
132 modified and which are new.

133 2.1 Section I – Summary of the dossier

134 A complete Section I as detailed in Section 10 of Annex 3 of Regulation (EC) No 429/2008 should
135 be submitted. A copy of the original Community authorisation for placing the feed additive on the
136 market, or the last renewal of authorisation, must be provided. The applicant has to provide a
137 summary of the dossier, detailing the scope of the application and any new information that has
138 become available since the previous authorisation/renewal in terms of identity and safety (and
139 efficacy, when relevant), and a list of all variations since the original authorisation or the last renewal
140 of the authorisation.

141 2.2 Section II – Identity, characterisation and conditions of use of the additive, 142 methods of analysis

143 A complete Section II should be provided for each dossier following the provisions of the Guidance
144 on the identity, characterisation and conditions of use of feed additives (EFSA FEEDAP Panel, 2017a)
145 and the Guidance on the characterisation of microorganisms used as feed additives or as production
146 organisms (EFSA FEEDAP Panel, 2018a), if appropriate.

147 The data provided in this section must allow confirmation of the compliance of the feed additive
148 with the specification detailed in the authorising regulation, including composition, activity,
149 impurities and any other provisions. The applicant is encouraged to apply the most recent and
150 precise analytical methodologies to identify and characterise the additive(s).

151 The applicant should describe in detail any changes in the manufacturing process, composition,
152 purity or activity in comparison with the authorised additive. The data provided in this Section should
153 reflect these changes. As an example, if the modifications made have an impact on the physico-
154 chemical properties of the additive, additional data on the physical properties (e.g., dusting
155 potential, particle size distribution), stability and/or homogeneity should be provided, as appropriate.

156 If the nature of the changes may have an effect on the safety (e.g., increased bioavailability, higher
157 user exposure) and/or the efficacy of the additive, additional studies may be required to address
158 these aspects.

159 Recent (not older than one year from the date of submission of the application) analytical data from
160 at least five batches for the composition of the additive and three for the purity should be provided,
161 following the requirements of the guidance documents mentioned above. In case of additives for

162 which there are not enough production batches available during the year previous to the submission
163 of the application, the data should refer to the five/three most recent batches.

164 The applicant should consider the availability of new or up to date analytical methods for the
165 identification and characterisation of the additive, as well as for its purity when providing the
166 information referred above.

167 For microorganisms used as additives or as production strains, the requirements of the Guidance on
168 the characterisation of microorganisms used as feed additives or as production organisms (EFSA
169 FEEDAP Panel, 2018a) should be followed, in particular for:

- 170 • Identification of each microorganism in the light of updated nomenclature
- 171 • antimicrobial resistance/susceptibility
- 172 • toxigenicity and pathogenicity
- 173 • description of the genetic modification for genetically modified microorganisms
- 174 • absence of viable cells and absence of DNA of the production strain, where relevant, for
175 fermentation products

176 For microorganisms qualifying for the qualified presumption of safety (QPS) approach to safety
177 assessment (EFSA, 2007), information should be provided to confirm the compliance with the
178 qualifications listed in the most recent Update of the list of QPS-recommended biological agents
179 intentionally added to food or feed as notified to EFSA.⁴ If the assessment of the identity and/or
180 qualifications do not confirm the QPS status of the microorganism(s), the applicant should consider
181 the implications for the safety assessment (e.g., need for toxicological studies) and provide data
182 accordingly.

183 Any new information on incompatibilities or interactions of the additive in feed with feed materials,
184 carriers, other approved additives or medicinal products since the last assessment should be
185 reported and documented.

186 The applicant should indicate whether the conditions of use of the additive remain the same as the
187 ones authorised or whether any modifications (e.g., reduction of the minimum concentration in feed,
188 increase of the maximum concentration in feed, change of the withdrawal time) are proposed. In
189 addition, if the applicant proposes new uses of the additive (e.g., new target species), these should
190 be clearly specified. In both cases, the implications for the need of new data/studies to support the
191 safety and/or efficacy of the additive should be considered and addressed in the relevant sections
192 of the dossier, following the provisions of the relevant guidance documents.

193 With regards to methods of analysis of the active substance (see section 2.6.1 of Regulation (EC)
194 No 429/2008), if verification studies as specified in 2.6.1.2 of such Regulation or the availability of
195 ISO/CEN methods were missing at time of the first application, the applicant shall provide that
196 missing information under Regulation (EC) No 378/2005. Corresponding methods of analysis shall
197 be used as reference methods and the related information shall be provided in the dossier.

⁴ [https://efsa.onlinelibrary.wiley.com/doi/toc/10.1002/\(ISSN\)1831-4732.QPS](https://efsa.onlinelibrary.wiley.com/doi/toc/10.1002/(ISSN)1831-4732.QPS)

198 2.3 Section III – Safety

199 2.3.1 General requirements

200 Evidence shall be presented that in the light of the current knowledge the additive remains safe
201 under the approved conditions of use for the target species, consumers, users and the environment.
202 An update on the safety covering the period since the original authorisation or the last renewal of
203 the authorisation should be presented.

204 In all the applications for renewal of the authorisation the following evidence must be provided:

- 205 • Results of the post marketing monitoring plan, when such monitoring is included in the
206 authorisation.
- 207 • Reports of any adverse effects including incidents/accidents (previously unknown effects,
208 severe effects of any type, increased incidence of known effects) for target animals,
209 consumers, users and the environment. These include any information deriving from any
210 complaint managing system, recalls and other information available in the context of good
211 manufacturing practice and Regulation (EC) No 183/2005⁵. The report on adverse effects
212 should include the nature of the effect(s), number of affected individuals/organisms,
213 outcome, conditions of use, and causality assessment and should consider the use in water
214 for drinking when it is authorised. When an adverse effect is identified, it should be
215 adequately followed up in the relevant section of the dossier (e.g. target species, consumer,
216 user, environment).
- 217 • Quantitative data on the production and use of the feed additive per target
218 species/categories and geographical distribution.
- 219 • Additional evidence to support the safety of the additive for the target animals, the
220 consumer, the user and the environment should be provided, based on the nature of additive
221 and its use, as described in the following sections.

222 2.3.2 Safety for the target species

223 Evidence should be provided that in the light of the current knowledge the additive remains safe for
224 the target species under the authorised conditions of use.

225 No additional information to support the safety for the target animals is required for those additives
226 listed in Section 2 of the Guidance on the assessment of the safety of feed additives for the target
227 species (EFSA FEEDAP Panel, 2017b), provided that the qualifications for the exclusion are met.

228 For those additives authorised for use in feed for all animal species and for which safety was derived
229 from studies in three terrestrial major species, evidence should be provided that the additive is safe
230 for fish (salmonids).

231 For those additives for which a maximum safe concentration in feed was derived using the results
232 of toxicological repeated dose studies in laboratory animals, the applicant should verify whether new
233 relevant studies are available that would allow identifying a different NOAEL or BMDL value than
234 that used to derive such maximum content should be provided. In case new toxicological studies

⁵ Regulation (EC) No 183/2005 of the European Parliament and of the Council of 12 January 2005 laying down requirements for feed hygiene. OJ L 35, 8.2.2005, p. 1.

235 are available from which a lower NOAEL/BMDL⁶ is identified, a new calculation of the maximum safe
236 concentration in feed should be done, following the provisions of the guidance on the safety for the
237 target species (EFSA FEEDAP Panel, 2017b).

238 When modifications in the composition/manufacturing affect the physicochemical properties of the
239 additive and may have an effect on the bioavailability of the active substance, implications on the
240 safety for the target species should be addressed following the provisions of the guidance on the
241 safety for the target species (EFSA FEEDAP Panel, 2017b).

242 When there is knowledge or evidence of adverse effects of the additive in the target species (e.g.
243 reported from the use of the additive (see 3.3.1) or from published literature), these should be
244 specifically addressed and the potential implications on the conditions of use of the additive
245 considered.

246 2.3.3 Safety for the consumer

247 Evidence should be provided that in the light of the current knowledge the additive remains safe for
248 the consumers under the authorised conditions of use.

249 No additional information to support the safety for the consumer is required for those additives listed
250 in Section 3.1 of the Guidance on the safety of the consumer (EFSA FEEDAP Panel, 2017c), provided
251 that the qualifications for the exclusion are met.

252 In all the other cases, the safety update should consider any new data/information available on the
253 absorption, distribution, metabolism and excretion (ADME), deposition and toxicological properties
254 of the additive or its components in the target species or laboratory animals, as well as the exposure
255 of the consumer to residues following the most up-to-date exposure assessment methodology (EFSA
256 FEEDAP Panel, 2017c).

257 In particular, the aspects detailed in the following sections should be addressed, as appropriate.

258 2.3.3.1 Residues

259 Information/data on residues of the additive and or its metabolite(s) in tissues and products of
260 animal origin is required:

- 261 a) when the authorising Regulation requires residue monitoring
- 262 b) when there is evidence that the metabolism in the target species may lead to a different set
263 of metabolites/residues compared to that already evaluated
- 264 c) when the modifications in the composition/manufacturing may have an effect on the
265 bioavailability of the active substance,
- 266 d) for any additives for which a health-based guidance value (HBGV) is established

267 For b), c) and d), the data/information on residues in tissues and products should be provided
268 following the provisions of the Guidance on the safety for the consumer (EFSA FEEDAP Panel,
269 2017c).

⁶ The updated guidance on the use of the benchmark dose approach in risk assessment ([EFSA Scientific Committee, 2017a](#)) should be used

270 2.3.3.2 Toxicological data/information

271 Any new information available regarding the toxicological and pharmacological properties of the
272 additive (in laboratory and target animals and in humans) should be provided. When new
273 assessments of the active substance(s)/additive are available from any scientific international bodies
274 (e.g., reassessing HBGV), these should be provided and the implications of the conclusions on the
275 need for any additional studies/data considered.

276 For those additives for which the original assessment included the evaluation of genotoxicity studies,
277 the compliance of that dataset with the requirements of the current guidance (EFSA FEEDAP Panel,
278 2017b and EFSA, 2011) should be confirmed. In addition, the following aspects should be carefully
279 considered in line with EFSA SC opinion on the 'Clarification of some aspects related to genotoxicity
280 assessment' (EFSA Scientific Committee, 2017b):

- 281 - The unscheduled DNA synthesis (UDS) assay is currently considered of low sensitivity, if
282 compared with other *in vivo* experimental approaches that have been validated in the last
283 few years (EFSA Scientific Committee, 2017b). For this reason, when existing data are re-
284 evaluated, only positive results are considered adequate to assess genotoxic potential, while
285 in case of negative outcome the reliability and significance of the study should be carefully
286 evaluated in a weight of evidence approach, before deciding whether more sensitive tests
287 such as TGR or *in vivo* comet assay would be needed to complete the assessment. The UDS
288 test is no longer recommended as an *in vivo* follow-up to positive results in *in vitro* gene
289 mutation tests.
- 290 - In case of negative results in a mammalian erythrocytes micronucleus test, toxicity to the
291 bone marrow in itself may provide sufficient evidence of bone marrow exposure to allow
292 concluding on the validity the study. Other lines of evidence, including toxicological and
293 toxicokinetic parameters, can be used to demonstrate bone marrow exposure (EFSA
294 Scientific Committee, 2017b). However, these lines of evidence should be assessed within a
295 weight of evidence approach to decide whether they might provide sufficient reassurance of
296 a valid negative test result. In the absence of information to confirm bone marrow exposure,
297 further testing would be required to conclude that the substance is not genotoxic (EFSA
298 Scientific Committee, 2011).

299 Special attention should be given on the assessment of the genotoxicity of chemical mixtures,
300 considering the Statement of the EFSA Scientific Committee on genotoxicity assessment of chemical
301 mixtures (EFSA Scientific Committee, 2019), in particular:

- 302 - The first step must be to characterise the mixture as fully as possible.
- 303 - For fully defined mixtures, the EFSA SC recommends applying a component-based
304 approach, i.e. assessing all components individually using all available information
305 including read across and (quantitative) structure-activity relationship (QSAR)
306 considerations about their genotoxic potential.
- 307 - For mixtures containing a substantial fraction of substances that have not been
308 chemically identified, the EFSA SC recommends that firstly the chemically defined
309 substances should be assessed individually for their potential genotoxicity (see above)
310 and then, if these prove negative, the genotoxic potential of the unidentified fraction
311 should be evaluated to complete the assessment of the mixture. Experimental testing of

312 the unidentified fraction or, if it is not feasible, testing of the whole mixture should be
313 undertaken.

314 It needs to be considered whether the assessment of all the new evidence on the toxicological profile
315 of the additive/active substance from the above would allow to set a health-based guidance value
316 or would lead to the modification of an existing one.

317 2.3.3.3 Exposure

318 For all the additives for which a HBGV is already established, consumer exposure, following the
319 provisions of the Guidance on consumer safety (EFSA FEEDAP Panel, 2017c), should be assessed.
320 This exposure assessment should be based in the most recent residue data available, as appropriate
321 (see 2.3.3.1).

322 In addition, any data on residues in food of animal origin deriving from uses of the active substance
323 other than as a feed additive (e.g., medicinal products) should be considered in the exposure
324 assessment.

325 Any new information on the exposure of the consumer to residues of the additive or its metabolites
326 via sources other than food of animal origin should be provided.

327 2.3.4 Safety for the user

328 Evidence should be provided that, in the light of the current knowledge, the additive remains safe
329 for the user under the authorised conditions of use. Special consideration should be given to:

- 330 - Experience in the manufacturing plant may be used to provide “real-life” evidence of effects
331 of the additive to people directly exposed to the additive. To this end, applicants should
332 include in the dossier records on the adverse effects on the workers of the manufacturing
333 plant and any other information on adverse effects to people exposed to the additive that
334 may be made known to the applicant via the complaint management system.
- 335 - Outcome of the assessment of the additive under the Registration, Evaluation, Authorisation
336 and Restriction of Chemicals (REACH) evaluation or existing Classification, Labelling
337 and Packaging (CLP) classification.

338 When the dataset submitted for the original assessment leading to the authorisation of the additive
339 contained a complete assessment of the safety for the user, the application for renewal may be
340 limited to the new evidence available since the last authorisation/renewal.

341 When the original dataset was not complete and did not allow the Panel to perform a complete
342 assessment of the safety of the additive for the user, the application for renewal should address the
343 data gaps in the former submission, in line with the requirements of the Guidance on the safety for
344 the user (EFSA FEEDAP Panel, 2012).

345 For additives for which a change in the manufacturing process/composition leads to a change in the
346 physical properties of the additive, additional studies may be needed. The need for and type of
347 studies will depend on the changes in exposure and/or potential new hazards introduced.

348 2.3.5 Safety for the environment

349 Evidence should be provided that, in the light of the current knowledge, the additive remains safe
350 for the environment under the authorised conditions of use.

351 No additional information on the safety for the environment in the framework of the renewal of
352 authorization is needed for the following additives, provided that the qualifications for the
353 exclusion are met:

- 354 - Additives intended to be used in feed for non food-producing animals only
- 355 - Natural substances already present in feedingstuffs or that would not increase their
356 concentration in the environment
- 357 - Additives extensively metabolised in the animal or rapidly degraded in nature
- 358 - Additives consisting of microorganisms that qualify for the QPS approach to safety
359 assessment
- 360 - Additives consisting of microorganisms naturally present in soil, plants or gastrointestinal
361 tract of the animals

362 Applicants should refer to the Guidance on the assessment of the safety of feed additives for the
363 environment (EFSA FEEDAP Panel, 2019) to assess whether new data/information would be
364 required.

365 2.4 Section IV – Efficacy

366 Efficacy studies are not required for the renewal of the authorisation of feed additives except:

- 367 - In the case of coccidiostats and histomonostats, new studies are required to obtain a
368 contemporary confirmation of efficacy. Evidence of the maintained susceptibility of *Eimeria*
369 *spp.* and *Histomonas meleagridis* to the coccidiostat and histomonostat, respectively, should
370 be provided in the form of sensitivity studies (with at least three sources (origins, farms) of
371 *Eimeria/Histomonas* strains (mixed infection)). These studies should have been completed
372 within the last year before the submission of the application and should follow the
373 requirements of the Guidance on the assessment of the efficacy of feed additives (EFSA
374 FEEDAP Panel, 2018b).
- 375 - When the applicant proposes amending or supplementing the conditions of the original
376 authorisation which may have an impact on the efficacy of the additive (e.g., a reduction of
377 the minimum recommended dose), additional efficacy studies may be required. In that case,
378 the requirements of the Guidance on the assessment of the efficacy of feed additives (EFSA
379 FEEDAP Panel, 2018b) should be followed.

380 2.5 Post-market monitoring

381 When a post-market monitoring plan was undertaken as a result of the original authorisation or the
382 last renewal of authorisation, the results of this plan should be reported under Section III.

383 If the applicant includes a proposal for amending or supplementing the conditions of the original
384 authorisation regarding the conditions concerning future monitoring, this should be clearly
385 described.

386 3 Means to provide evidence of safety (and efficacy, when 387 relevant)

388 Applicants should assess which is the best means to provide evidence of the safety (and when
389 relevant, efficacy) of the additive subject to the application for renewal of the authorisation, as
390 required in the previous chapters. The following sections detail common approaches that can be
391 used to retrieve the information in addition to the mandatory requirements listed in section 2.3.1.
392 However, applicants may choose to submit other types of information/evidence provided that they
393 fully address the requirements above and are properly justified.

394 3.1 Extensive literature searches

395 An extensive literature search may provide information on the safety of the feed additive under the
396 authorised conditions of use. The analysis of these data must establish that the active
397 substance(s)/agent(s) in literature studies is (are) identical to that under application or, if not, would
398 still allow conclusions on the additive under application to be made⁷; for additives produced by
399 fermentation, identity includes the production strain. For additives consisting of a mixture, the
400 extensive literature search should cover all the components of the mixture (individually and the
401 complete mixture).

402 The extensive literature search should follow the principles detailed in the guidance on the
403 assessment of the safety of feed additives for the target species (EFSA FEEDAP Panel, 2017b) and
404 should cover at least the period since the last assessment until not more than 6 months before the
405 date of submission of the application for renewal.

406 Relevant information sources should be searched in a structured manner. The applicant should make
407 reasonable efforts to locate all sources of relevant information and provide reasons for the selection
408 of such sources. Bibliographic databases (including at least agricultural/aquacultural and
409 medical/veterinary databases) which record documents such as journals, reports, conference
410 proceedings and books should be searched. In addition, the search should consider sources other
411 than bibliographic databases, such as reference lists of full-text journal articles (e.g. reviews),
412 websites of conferences or organisations.

413 Special attention should be paid to the search terms and search strategy used to ensure the
414 sensitivity of the search. Search strings should be broad enough to yield studies on the relevant
415 end-points with regard to the safety for the target animals, consumers, users and environment
416 detailed in the relevant guidance documents, and should include any specific known (adverse)
417 effects (e.g., genotoxicity, endocrine effects) of the additive.

418 Applicants should follow the recommendations of the Technical manual for performing electronic
419 literature searches in food and feed safety (Glanville et al., 2014) when performing the searches. In
420 particular, the following should be considered:

- 421 - To design a sensitive search strategy, searchers should employ a combination of indexing
422 terms when available (selected from the indexing language or thesaurus) and a wide range
423 of free-text terms. When choosing free-text terms to use in a search strategy the reviewer
424 should consider as many synonyms and related terms as possible. It is important to consider

⁷ The literature search could also be used to provide justifications for the read-across.

425 differences in spelling and terminology, use of abbreviations, identification numbers (e.g.,
426 CAS number, FLAVIS), use of the generic and brand names of the additive.

427 - To use appropriately boolean operators, truncation, wildcards or proximity operators.

428
429 The search methodology should be documented and reported in detail to ensure transparency and
430 enable the evaluation and replication of the search:

431 For database searches:

- 432 - the name of the database and the service provider used;
- 433 - the date of the search and the date range searched;
- 434 - any limits placed on the search such as language or publication status;
- 435 - the full search strategy (all terms and set combinations) and the number of records retrieved.

436 For sources other than bibliographic databases:

437 1) Websites and journal table of contents

- 438 - the name of the resource (i.e. website name, the journal name in case of searching in specific
439 tables of contents);
- 440 - the URL (uniform resource locator, the internet address);
- 441 - the date on which the search was conducted and the date range of the search, or the dates,
442 volumes and issues in the case of table of contents;
- 443 - the method of searching, e.g. browsing, using the search engine or scanning tables;
- 444 - any limits applied to the search (e.g. publication types);
- 445 - the search terms used and the number of relevant summary records or full-text documents
446 retrieved.

447 2) References lists

- 448 - the bibliographic details of the documents whose reference lists were scanned;
- 449 - the number of relevant bibliographic references retrieved.

450 Once the search is completed and duplicate publications have been removed, the retrieved
451 publications should be assessed for their relevance. Relevance reflects the extent to which the study
452 is appropriate to assess the safety (and when relevant, efficacy) of the additive subject to the
453 application. The selection process will assess the studies against inclusion/exclusion criteria clearly
454 defined *a priori*.

455 The following information concerning the selection of publications should be clearly reported:

- 456 - Exclusion and inclusion criteria applied to the papers retrieved.
- 457 - Expertise and number of the reviewers involved in the selection process.
- 458 - Description of stages of the selection process (e.g. stepwise approach with a first stage
459 assessing title and abstract and a second assessment based on the full text).
- 460 - Final number of papers reviewed and excluded papers on each stage of the selection process,
461 if applicable, with reasons for exclusion.

- 462 - A list of the bibliographic references for all relevant publications selected.
- 463 - A list of the bibliographic references for the unobtainable publications (if any), with
464 explanation why could not be obtained.

465 Applicants should provide a summary table of the outcome of the search and selection process
466 where the relevant studies are described. The summary table should include, as a minimum,
467 information on the test item (and relation with the product under assessment), concentration/doses,
468 animal species (as appropriate), duration, end-points assessed and summary of the effects
469 observed.

470 The list of relevant references included should be provided in '.RIS' format⁸. Copies of the relevant
471 papers should be provided. The applicant must ensure that terms and conditions asserted by any
472 copyright holder of publications or information submitted to EFSA are fully satisfied. The applicant
473 should consult with copyright licensing authorities (i.e. at national level) for guidance on purchasing
474 copyright licenses to reproduce any publications provided to EFSA. The applicant remains solely
475 responsible and liable for obtaining all necessary authorisations and rights to use, reproduce and
476 share the publications provided to EFSA.

477 3.2 New studies

478 The applicant may choose to submit new experimental studies to provide evidence on any aspects
479 of the safety of the additive and, if relevant, of its efficacy. Such studies should be performed and
480 reported according to the relevant guidance documents in force at the time of the submission of the
481 application.

482 For studies for the safety for the target species, these should be completed within the 3 years before
483 the submission of the application and should reflect the current EU farming/production conditions.

484 4 Other requests linked to the application for the renewal of the 485 authorisation

486 It is recognised that an application for the renewal of an existing authorisation can be used to
487 propose modifications to the existing authorisation (modification of the conditions of use) or the
488 request for the authorisation for new uses of the feed additive (e.g., new target species). When the
489 application for renewal contains requests for the modification of the conditions of the authorisation
490 or new uses of the feed additive, all the aspects related to characterisation of the additive and its
491 conditions of use, safety and efficacy, where relevant, linked to such modifications/new uses should
492 be addressed following the relevant guidance documents applicable at the time of the submission
493 of the application.

494 5 References

495 EFSA (European Food Safety Authority), 2007. Opinion of the Scientific Committee on a request from EFSA on
496 the introduction of a Qualified Presumption of Safety (QPS) approach for assessment of selected
497 microorganisms referred to EFSA. The EFSA Journal (2007) 587, 1-16.

⁸ RIS is a standardized tag format that enables the exchange of bibliographic information. It is supported by a number of reference manager software

498 EFSA (European Food Safety Authority), 2011. Scientific opinion on genotoxicity testing strategies applicable
499 to food and feed safety assessment. EFSA Journal 2011;9(9):2379, 68 pp.
500 <https://doi.org/10.2903/j.efsa.2011.2379>

501 EFSA FEEDAP Panel (EFSA Panel on Additives and Products or Substances used in Animal Feed), 2013.
502 Guidance on the renewal of the authorisation of feed additives. EFSA Journal 2013;11(10):3431, 8 pp.
503 [doi:10.2903/j.efsa.2013.3431](https://doi.org/10.2903/j.efsa.2013.3431)

504 EFSA FEEDAP Panel (EFSA Panel on Additives and Products or Substances used in Animal Feed), 2012.
505 Guidance on studies concerning the safety of use of the additive for users/workers. EFSA Journal
506 2012;10(1):2539, 5 pp. [doi:10.2903/j.efsa.2012.2539](https://doi.org/10.2903/j.efsa.2012.2539)

507 EFSA FEEDAP Panel (EFSA Panel on Additives and Products or Substances used in Animal Feed), Rychen G,
508 Aquilina G, Azimonti G, Bampidis V, Bastos ML, Bories G, Chesson A, Cocconcelli PS, Flachowsky G, Gropp J,
509 Kolar B, Kouba M, López-Alonso M, López Puente S, Mantovani A, Mayo B, Ramos F, Saarela M, Villa RE,
510 Wallace RJ, Wester P, Anguita M, Galobart J and Innocenti ML, 2017. Guidance on the identity, characterisation
511 and conditions of use of feed additives. EFSA Journal 2017a;15(10):5023, 12 pp.
512 <https://doi.org/10.2903/j.efsa.2017.5023>

513 EFSA FEEDAP Panel (EFSA Panel on Additives and Products or Substances used in Animal Feed), Rychen G,
514 Aquilina G, Azimonti G, Bampidis V, Bastos ML, Bories G, Chesson A, Cocconcelli PS, Flachowsky G, Gropp J,
515 Kolar B, Kouba M, López-Alonso M, López Puente S, Mantovani A, Mayo B, Ramos F, Saarela M, Villa RE,
516 Wallace RJ, Wester P, Anguita M, Galobart J, Innocenti ML and Martino L, 2017. Guidance on the assessment
517 of the safety of feed additives for the target species. EFSA Journal 2017b;15(10):5021, 19 pp.
518 <https://doi.org/10.2903/j.efsa.2017.5021>

519 EFSA FEEDAP Panel (EFSA Panel on Additives and Products or Substances used in Animal Feed), Rychen G,
520 Aquilina G, Azimonti G, Bampidis V, Bastos ML, Bories G, Chesson A, Cocconcelli PS, Flachowsky G, Gropp J,
521 Kolar B, Kouba M, López-Alonso M, López Puente S, Mantovani A, Mayo B, Ramos F, Saarela M, Villa RE,
522 Wallace RJ, Wester P, Anguita M, Dujardin B, Galobart J and Innocenti ML, 2017. Guidance on the assessment
523 of the safety of feed additives for the consumer. EFSA Journal 2017c;15(10):5022, 17 pp.
524 <https://doi.org/10.2903/j.efsa.2017.5022>

525 EFSA FEEDAP Panel (EFSA Panel on Additives and Products or Substances used in Animal Feed), Rychen G,
526 Aquilina G, Azimonti G, Bampidis V, Bastos ML, Bories G, Chesson A, Cocconcelli PS, Flachowsky G, Gropp J,
527 Kolar B, Kouba M, López-Alonso M, López Puente S, Mantovani A, Mayo B, Ramos F, Saarela M, Villa RE,
528 Wallace RJ, Wester P, Glandorf B, Herman L, Kärenlampi S, Aguilera J, Anguita M, Brozzi R and Galobart J,
529 2018a. Guidance on the characterisation of microorganisms used as feed additives or as production organisms.
530 EFSA Journal 2018;16(3):5206, 24 pp. <https://doi.org/10.2903/j.efsa.2018.5206>

531 EFSA FEEDAP Panel (EFSA Panel on Additives and Products or Substances used in Animal Feed), Rychen G,
532 Aquilina G, Azimonti G, Bampidis V, Bastos ML, Bories G, Chesson A, Cocconcelli PS, Flachowsky G, Gropp J,
533 Kolar B, Kouba M, López-Alonso M, López Puente S, Mantovani A, Mayo B, Ramos F, Saarela M, Villa RE,
534 Wallace RJ, Wester P, Anguita M, Galobart J, Innocenti ML and Martino L, 2018b. Guidance on the assessment
535 of the efficacy of feed additives. EFSA Journal 2018;16(5):5274, 25 pp.
536 <https://doi.org/10.2903/j.efsa.2018.5274>

537 EFSA FEEDAP Panel (EFSA Panel on Additives and Products or Substances used in Animal Feed), Bampidis V,
538 Bastos ML, Christensen H, Dusemund B, Kouba M, Kos Durjava M, López-Alonso M, López Puente S, Marcon
539 F, Mayo B, Pechová A, Petkova M, Ramos F, Sanz Y, Villa RE, Woutersen R, Brock T, Knecht J, Kolar B, Beelen
540 P, Padovani L, Tarrés-Call J, Vettori MV and Azimonti G, 2019. Guidance on the assessment of the safety of
541 feed additives for the environment. EFSA Journal 2019;17(4):5648, 78 pp.
542 <https://doi.org/10.2903/j.efsa.2019.5648>

543 EFSA Scientific Committee, Hardy A, Benford D, Halldorsson T, Jeger MJ, Knutsen KH, More S, Mortensen A,
544 Naegeli H, Noteborn H, Ockleford C, Ricci A, Rychen G, Silano V, Solecki R, Turck D, Aerts M, Bodin L, Davis
545 A, Edler L, Gundert-Remy U, Sand S, Slob W, Bottex B, Abrahantes JC, Marques DC, Kass G and Schlatter JR,

546 2017a. Update: Guidance on the use of the benchmark dose approach in risk assessment. EFSA Journal
547 2017;15(1):4658, 41 pp. <https://efsa.onlinelibrary.wiley.com/doi/pdf/10.2903/j.efsa.2017.4658>

548 EFSA Scientific Committee, Hardy, A, Benford, D, Halldorsson, T, Jeger, M, Knutsen, HK, More, S, Naegeli,
549 H, Noteborn, H, Ockleford, C, Ricci, A, Rychen, G, Silano, V, Solecki, R, Turck, D, Younes, M, Aquilina,
550 G, Crebelli, R, Gürtler, R, Hirsch-Ernst, KI, Mosesso, P, Nielsen, E, van Benthem, J, Carfi, M, Georgiadis,
551 N, Maurici, D, Parra Morte, J and Schlatter, J, 2017b. Scientific Opinion on the clarification of some aspects
552 related to genotoxicity assessment. EFSA Journal 2017;15(12):5113, 25
553 pp. <https://doi.org/10.2903/j.efsa.2017.5113>

554 EFSA Scientific Committee, More, S, Bampidis, V, Benford, D, Boesten, J, Bragard, C, Halldorsson,
555 T, Hernandez-Jerez, A, Hougaard-Bennekou, S, Koutsoumanis, K, Naegeli, H, Nielsen, SS, Schrenk, D, Silano,
556 V, Turck, D, Younes, M, Aquilina, G, Crebelli, R, Gürtler, R, Hirsch-Ernst, KI, Mosesso, P, Nielsen, E, Solecki,
557 R, Carfi, M, Martino, C, Maurici, D, Parra Morte, J and Schlatter, J, 2019. Statement on the genotoxicity
558 assessment of chemical mixtures. EFSA Journal 2019;17(1):5519, 11
559 pp. <https://doi.org/10.2903/j.efsa.2019.5519t>

560 Glanville J, Varley D, Brazier H, Arber M, Wood H and Dooley G, 2014. Inventory of sources of scientific
561 evidence relevant to EFSA's risk assessments and information sessions on literature searching techniques
562 (CFT/EFSA/SAS/2011/03 Inventory Report) [including the supporting information "efs3593e-sup-0001-
563 SupInfo.pdf": Glanville J, Wood H, Arber M, Varley D, Frampton G and Brazier H. Technical manual for
564 performing electronic literature searches in food and feed safety]. EFSA Supporting Publications, 11, 1–73.
565 Available from <http://onlinelibrary.wiley.com/doi/10.2903/sp.efsa.2014.EN-593/pdf>

566 Glossary and/or abbreviations and/or acronyms

BMDL	benchmark dose level
CFU	colony-forming unit
EC	European Commission
ECHA	European Chemicals Agency
EURL	European Union Reference Laboratory
NOAEL	no observed adverse effect level

567